MetaCap

LeonaBio (LONA) vs Pelthos Therapeutics (PTHS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

LeonaBio (LONA) has outperformed Pelthos Therapeutics (PTHS) over the past year, losing 56.1% versus a loss of 74.9%. LeonaBio is the larger company by market cap ($26.4 million vs $25.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LONA-56.13%PTHS-74.88%
+165%+39%-86%
Nov 21, 20251 yearNov 20, 2026
LONA-94.36%PTHS-86.71%
+15%-42%-100%
Feb 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LONA versus PTHS key metrics
MetricLONAPTHS
Share price$2.02$6.38
Market cap$26.41M$25.08M
1-day change-17.89%-8.73%
YTD return-73.32%-79.42%
1-year return-56.13%-74.88%
5-year return-98.55%—
EPS (TTM)$-22.20$-23.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$16.80M
Net income (latest FY)$-105.61M$-43.32M
Gross margin—76.25%
Operating margin—-193.09%
Net margin—-257.93%
52-week high$14.21$31.62
52-week low$1.91$6.02
Distance from 52-week high-85.78%-79.82%
Analyst consensusnonestrong_buy
Avg. price target upside+757.92%+732.92%
Average volume195.37K54.38K
Shares outstanding13.08M3.93M
Employees1992
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LONA has outperformed PTHS by 18.7 percentage points over the past year.

About LeonaBio

LONA stock →

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees

About Pelthos Therapeutics

PTHS stock →

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

LONA vs PTHS FAQ

Which is bigger, LeonaBio or Pelthos Therapeutics?

LeonaBio (LONA) is larger, with a market capitalization of $26.41M compared with $25.08M for Pelthos Therapeutics (PTHS).

Which stock has performed better over the past year, LONA or PTHS?

LONA returned -56.13% over the past 12 months, compared with -74.88% for PTHS (price return, excluding dividends). Past performance does not predict future results.

Are LeonaBio and Pelthos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons